Kairos Pharma Ltd. (KAPA)
AMEX: KAPA
· Real-Time Price · USD
1.16
-0.04 (-3.33%)
At close: Aug 18, 2025, 3:59 PM
1.17
1.30%
After-hours: Aug 18, 2025, 05:40 PM EDT
Kairos Pharma Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 40K | 40K | 40K | 40K | 40K | 40K | 40K | 40K | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -40K | -40K | -40K | -40K | -40K | -40K | -40K | -40K | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -1.46M | -1.27M | -1.45M | -383K | -222K | -287K | -1.09M | -287K | -212K | -126K | -180K | -124K | -120K | -147K |
Interest Income | 34K | 4K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -1.42M | -1.26M | -980K | -1.05M | -253K | -323K | -1.12M | -312K | -236K | -146K | -196K | -234K | -385K | -235K |
Net Income | -1.42M | -1.26M | -980K | -1.05M | -253K | -323K | -1.12M | -312K | -236K | -146K | -196K | -234K | -385K | -235K |
Selling & General & Admin | 960K | 773K | 1.23M | 329K | 119K | 82K | 1.04M | 214K | 176K | 120K | 132K | 124K | 114K | 114K |
Research & Development | 496K | 493K | 172K | 14K | 63K | 165K | 7K | 33K | 36K | 6K | 48K | n/a | 6K | 33K |
Other Expenses | -118K | n/a | 40K | 40K | 40K | 40K | 40K | 40K | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 1.34M | 1.27M | 1.45M | 383K | 222K | 287K | 1.09M | 287K | 212K | 126K | 180K | 124K | 120K | 147K |
Interest Expense | n/a | n/a | 133K | 664K | 31K | 36K | 29K | 25K | 24K | 20K | n/a | 110K | 265K | 88K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 1.38M | 1.27M | 1.45M | 383K | 222K | 287K | 1.09M | 287K | 212K | 126K | 180K | 124K | 120K | 147K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 17.21M | 15.88M | 13.74M | 10.91M | 12.84M | 10.56M | 10.47M | 11.22M | 10.33M | 10.33M | 10.34M | 10.25M | 10.18M | 10.18M |
Shares Outstanding (Diluted) | 17.21M | 15.88M | 13.74M | 10.91M | 12.84M | 10.56M | 10.47M | 11.22M | 10.33M | 10.33M | 10.34M | 10.25M | 10.18M | 10.18M |
EPS (Basic) | -0.08 | -0.08 | -0.07 | -0.1 | -0.02 | -0.03 | -0.11 | -0.03 | -0.02 | -0.01 | -0.02 | -0.02 | -0.04 | -0.02 |
EPS (Diluted) | -0.08 | -0.08 | -0.07 | -0.1 | -0.02 | -0.03 | -0.11 | -0.03 | -0.02 | -0.01 | -0.02 | -0.02 | -0.04 | -0.02 |
EBITDA | -1.46M | -1.27M | -807K | -880K | -182K | -247K | -1.05M | -247K | -172K | -86K | -140K | -84K | -80K | -107K |
EBIT | -1.42M | -1.26M | -847K | -920K | -222K | -287K | -1.09M | -287K | -212K | -126K | -180K | -124K | -120K | -147K |
Depreciation & Amortization | n/a | 40K | 40K | 40K | 40K | 40K | 40K | 40K | 40K | 40K | 40K | 40K | 40K | 40K |